Hakimsons (Impex) products and prices in Pakistan
Importer / marketer Its products are registered under a DRAP Drug Sale Licence (DSL), typically imported finished products. Source: DRAP.
Follow price changes 🔒 Company report (Pharma Pro)Private pharmaceutical importer, marketer and distributor · Karachi · Pakistan
Karachi-based importer, marketer and distributor specializing in biological, plasma-derived and other specialized pharmaceutical products.
Hakimsons (Impex) products in Pakistan
Hakimsons (Impex) (Pvt.) Ltd has 13 medicine presentations registered in Pakistan under 13 brands, covering 10 generic medicines. Most of its products are in Oncology & immunology, Vaccines & immunologicals and Anti-infectives. Its brands with the most registered strengths and packs are Casglo 50 (Caspofungin), Casglo 70 (Caspofungin), Celdach 100 (Oxaliplatin) and Celdach 50 (Oxaliplatin). 13 products have an official DRAP price on MedInfoBase. See all 13 brands A to Z
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Private pharmaceutical importer, marketer and distributor
- Address
- Hakimsons Building, 19 West Wharf Road, Karachi 74000, Pakistan · 74000
- Website
- hakimsons.com.pk ↗
- Phone
- +92 21 32314765; +92 21 32314766; +92 21 32312631; +92 21 32315365
- Official contact
- Contact page ↗
- Corporate source details checked
- 26 Oct 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
See where Hakimsons (Impex) (Pvt.) Ltd. is priced against the market
7 of its products have like-for-like competitors. Pharma Pro shows how many are priced below, near or above the market median, the company's overall price position, and product-by-product examples.
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
🔒 3 more overlapping companies, with shared-generic detail, in Pharma Pro. Unlock
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Berirab P Anti-Rabies Immunoglobulin (HumanSource observed | — | — | Injection | Per syringe | 021056Official source ↗ | No indexed price | — | — |
| Casglo 50 | Caspofungin | 50 mg | Powder for concentrate for solution for infusion | 1's | 128805 | PKR 32,278.65 | PKR 32,278.65/vial/unit | 🔒 Pharma Pro |
| Casglo 70 | Caspofungin | 70 mg | Powder for concentrate for solution for infusion | 1's | 128806 | PKR 32,278.65 | PKR 32,278.65/vial/unit | 🔒 Pharma Pro |
| Celdach 100 | Oxaliplatin | 100 mg | Injection | Per vial | 072564 | PKR 38,688.31 | PKR 38,688.31/vial/unit | 🔒 Pharma Pro |
| Celdach 50 | Oxaliplatin | 50 mg | Injection | Per vial | 072565 | PKR 19,751.41 | PKR 19,751.41/vial/unit | 🔒 Pharma Pro |
| Celtere 20 | Docetaxel | 20 mg | Injection | Per vial | 072559 | PKR 16,289.82 | PKR 16,289.82/vial/unit | 🔒 Pharma Pro |
| Celtex 30 | Paclitaxel (albumin-bound nanoparticles) | 30 mg | Injection | Per vial | 072563 | PKR 12,217.36 | PKR 12,217.36/vial/unit | No comparator |
| Celzar 1000 | Gemcitabine | 1000 G | Injection | Per vial | 072562 | PKR 16,961.77 | PKR 16,961.77/vial/unit | No comparator |
| Celzar 200 | Gemcitabine | 200 G | Injection | Per vial | 072561 | PKR 3,410.68 | PKR 3,410.68/vial/unit | No comparator |
| Cosalon 50 | Bicalutamide | 50 mg | Tablet | 10'S | 074857 | PKR 2,250.03 | PKR 225.00/tablet | 🔒 Pharma Pro |
| Equirab | Equine rabies immunoglobulin | 1000 IU/5 mL | Injection | (1's pack) | 052223 | PKR 2,137.88 | PKR 2,137.88/vial/unit | No comparator |
| PRIVIGEN | Human normal immunoglobulin (IgG) | 10% | Intravenous infusion | 25 ml Bottle | 087405 | PKR 30,788.75 | PKR 1,231.55/mL | No comparator |
| Rhophylac Anti-D ImmunoglobulinSource observed | — | 300 mcg | — | Per syringe | 041161Official source ↗ | No indexed price | — | — |
| Snake Venom AntiSerum Snake Venom AntiSerumSource observed | — | — | — | (1's pack) | 053882Official source ↗ | No indexed price | — | — |
| Snake Venom AntiSerum Snake Venom AntiSerumSource observed | — | — | — | (1's pack) | 053882Official source ↗ | No indexed price | — | — |
| Tetagam-P Anti-Tetanus ImmunoglobulinSource observed | — | — | — | Per syringe | 047505Official source ↗ | No indexed price | — | — |
| VaxiRab-N | Rabies vaccine, inactivated (purified chick embryo cell culture) | ≥2.5 IU/dose | Lyophilized powder for solution for IM/ID injection | 1's | 106824 | PKR 2,462.61 | PKR 2,462.61/vial/unit | No comparator |
| Xelocel 500 | Capecitabine | 500 mg | Tablet | 12 x 10's | 078107 | PKR 35,633.98 | PKR 296.95/tablet | 🔒 Pharma Pro |
| Zinnia FSource observed | Levonorgestrel | — | Tablet | 3 x 28's | 101939Official source ↗ | No indexed price | — | — |
All 13 Hakimsons (Impex) brands in Pakistan
- Casglo 50 Caspofungin · 50 mg infusion
- Casglo 70 Caspofungin · 70 mg infusion
- Celdach 100 Oxaliplatin · 100 mg injection
- Celdach 50 Oxaliplatin · 50 mg injection
- Celtere 20 Docetaxel · 20 mg injection
- Celtex 30 Paclitaxel (albumin-bound nanoparticles) · 30 mg injection
- Celzar 1000 Gemcitabine · 1000 G injection
- Celzar 200 Gemcitabine · 200 G injection
- Cosalon 50 Bicalutamide · 50 mg tablet
- Equirab Equine rabies immunoglobulin · 1000 IU/5 mL injection
- PRIVIGEN Human normal immunoglobulin (IgG) · 10% infusion
- VaxiRab-N Rabies vaccine, inactivated (purified chick embryo cell culture) · ≥2.5 IU/dose injection
- Xelocel 500 Capecitabine · 500 mg tablet
Hakimsons (Impex): common questions
How many products does Hakimsons (Impex) have in Pakistan?
Hakimsons (Impex) (Pvt.) Ltd has 13 registered medicine presentations in Pakistan, sold under 13 brands and covering 10 generic medicines.
What are the main brands of Hakimsons (Impex)?
By number of registered strengths and packs, its largest brands are Casglo 50 (Caspofungin), Casglo 70 (Caspofungin), Celdach 100 (Oxaliplatin), Celdach 50 (Oxaliplatin) and Celtere 20 (Docetaxel). This is not a sales ranking.
Which therapy areas does Hakimsons (Impex) cover?
The most products are in Oncology & immunology (8), Vaccines & immunologicals (3) and Anti-infectives (2).
Where can I see Hakimsons (Impex) medicine prices?
Open any brand in the list above for its official DRAP price, pack sizes, price history and other brands of the same medicine.
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.